Generic name |
fingolimod |
Strength |
0.5 mg |
Form |
capsule |
Special Authority criteria |
Approval period |
---|---|
Initial: As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) which is diagnosed according to the current clinical criteria and magnetic resonance imaging (MRI) evidence. Combination therapy is not covered. This drug is for the treatment of patients 18 years of age and older who meet ALL of the following criteria:
|
15 months |
Renewal:
|
24 months |